Search Results
Your search for 3 matches 15039 pages
Showing 9551 - 9600LATITUDE Trial: Adding Abiraterone and Prednisone to Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer
As reported in the Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Fizazi et al, the phase III LATITUDE trial has shown that the addition of abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy resulted in marked improvements in...
ASCO 2017: The IDEA Collaboration: Global Study Sets New Risk-Based Standard to Personalize Chemotherapy for Colon Cancer After Surgery
After surgery for lymph node–positive colon cancer (stage III), some patients may need only half of the long-standing standard course of chemotherapy. In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months in patients with...
ASCO 2017: OlympiAD Trial: Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer
Findings from a phase III clinical trial of about 300 women may introduce poly ADP ribose polymerase (PARP) inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced the chance of progression of advanced,...
Todd M. Gibson, PhD, on Childhood Cancer Survivors: Chronic Disease Trends
Todd M. Gibson, PhD, of St. Jude Children’s Research Hospital, discusses results from the Childhood Cancer Survivor Study, which showed a reduction in serious chronic morbidity measured across 3 decades. (LBA10500)
ASCO 2017: Larotrectinib Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers
Scientists may have developed the first targeted, oral, tumor-type agnostic therapy—an agent that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment...
ASCO 2017: ProfiLER Trial: Routine Genomic Testing Feasible, but Only a Subset of Patients May Benefit
Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing is not yet routine care. A...
ASCO 2017: New High-Intensity Genomic Sequencing Approach Detects Circulating Tumor DNA at a High Rate
In a study of 124 patients with advanced breast, lung, and prostate cancers, a new high-intensity genomic sequencing approach detected circulating tumor DNA at a high rate. In 89% of patients, at least one genetic change detected in the tumor was also detected in the blood. Overall, 627 (73%)...
ASCO 2017: LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer...
ASCO 2017: STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer
The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone vs 83% with standard...
ASCO 2017: Single-Dose Radiotherapy as Effective as Multiple Fractions in Relieving Symptoms of Spinal Cord Compression
Spinal cord compression is a common complication in people with metastatic cancer and is a major detriment to quality of life. Radiation treatment is widely used to relieve pain and other symptoms, but there is no standard recommended schedule, and approaches currently vary. Findings from a phase...
ASCO 2017: Low Testosterone Level After Testicular Cancer Is Common, Linked to Chronic Health Problems
In a large study, 38% of 491 testicular cancer survivors had low testosterone levels. Compared with survivors with normal testosterone levels, survivors with low testosterone levels were more likely to have a range of chronic health problems, including high blood pressure, diabetes, erectile...
ASCO 2017: Conquer Fear Intervention Lowers Young Breast Cancer Survivors’ Fear of Cancer Recurrence
About 50% of all cancer survivors and 70% of young breast cancer survivors report a moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life. Yet interventions to alleviate ...
ASCO 2017: Steady Decrease in Severe Health Problems for Childhood Cancer Survivors
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems...
ASCO 2017: CALM Intervention Relieves Distress in Patients With Advanced Cancer
Advanced cancer triggers enormous distress and brings challenges that can seem overwhelming. Yet most cancer centers lack systematic approaches to help patients and families manage the practical and emotional toll of advanced cancer. Findings from a randomized clinical trial of 305 patients with...
Celebrating Cancer Survivorship
Sunday, June 4, 2017, marks the 30th anniversary of National Cancer Survivors Day. Here’s a look at the progress that has been made over the past 2 to 3 decades in reducing cancer incidence and cancer deaths and the challenges that remain. Increasing Rates of Cancer Survivorship In 1971, the...
ATS 2017: Among All Cancers, Lung Cancer Appears to Put Patients at Greatest Suicide Risk
A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the 2017 American Thoracic Society International Conference (Abstract 8321). Researchers analyzed 3,640,229 patients in ...
Japanese Phase III Trial of Alectinib vs Crizotinib in ALK-Positive NSCLC
The Japanese phase III J-ALEX trial has shown improved progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in ALK inhibitor–naive patients with ALK-positive non–small-cell lung cancer (NSCLC). Results were reported by Hida et al in The Lancet. Study Details In...
Image-Guided Biopsies Accurately Identify Patients With Breast Cancer Who Achieve Pathologic Complete Response Following Neoadjuvant Therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response after neoadjuvant systemic therapy consisting of chemotherapy and/or targeted therapy. Should the...
Study Finds Hypofractionated Whole-Breast Irradiation Leads Breast Cancer Radiation Therapies in Cost-Effectiveness, Quality of Life
In a study of three radiation therapies for early-stage breast cancer, one treatment option stands out as offering the most value based on factors including health outcomes, cost-effectiveness, and quality of life. The treatment—hypofractionated whole-breast irradiation—also requires...
2017 Fellows of the American Society of Clinical Oncology (FASCO)
The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the individuals at risk for, or with...
Pembrolizumab in Advanced PD-L1–Positive Endometrial Cancer
Pembrolizumab (Keytruda) showed activity in previously treated patients with advanced programmed cell death ligand 1 (PD-L1)–positive endometrial cancer in a cohort of the phase Ib KEYNOTE-028 study. These findings were reported in the Journal of Clinical Oncology by Ott et al. Study Details ...
After Nearly 4 Decades of Research, W.K. Alfred Yung, MD, Sees a New Era Ahead for Advances in Brain Tumors
After he was not accepted into the University of Hong Kong, plan B for W.K. Alfred Yung, MD, was to leave his country and immigrate to the United States to attend the University of Minnesota in Minneapolis—a move he considers more exile than choice. Born on April 8, 1948, in Hong Kong, Dr. Yung...
AACR Honors Mina J. Bissell, PhD, FAACR, With Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) recognized Mina J. Bissell, PhD, FAACR, with the 14th AACR Award for Lifetime Achievement in Cancer Research during the 2017 AACR Annual Meeting in Washington, DC. The AACR Award for Lifetime Achievement in Cancer Research was established in 2004 ...
Leader in International Clinical Trials, Robert L. Comis, MD, FASCO, Dies at 71
Robert L. Comis, MD, FASCO, Co-Chair of the ECOG-ACRIN Cancer Research Group, succumbed to a sudden illness at his home and died on May 10, 2017, at the age of 71. A giant in national and international clinical research since 1977, Dr. Comis is known as a champion of patient access to cancer...
For Eric P. Winer, MD, Empathy and a Sense of Purpose Lead to a Career in Oncology
Eric Paul Winer, MD, was born in Boston in 1956, a year when gasoline was 22 cents a gallon and IBM released the world’s first computer with a hard drive. His grandfather on his mother’s side had hemophilia and died 5 years before Dr. Winer was born. Although there was a 50% chance that Dr. Winer...
Conquer Cancer Foundation of ASCO Awards Celebrate Innovation and Diversity
The Conquer Cancer Foundation of ASCO (CCF) is proud to recognize the recipients of its 2017 CCF Merit Awards and its Diversity Awards, which include the Medical Student Rotation Award for Underrepresented Populations and the Resident Travel Award for Underrepresented Populations. Geared toward...
SU2C Awards Innovative Research Grants in Immuno-oncology to 10 Early-Career Scientists
Stand Up to Cancer (SU2C) has announced the award of $7.5 million in Innovative Research Grants focused on immuno-oncology to 10 early-career scientists, in a program funded by a grant from Bristol-Myers Squibb Company (BMS), an SU2C Visionary Supporter. These awards were announced at the 2017...
At the Forefront of Cancer Genetics, Bert Vogelstein, MD, Calls for Focus on Early Detection and Prevention
Bert Vogelstein, MD, was born on June 2, 1949, at The Johns Hopkins Hospital in Baltimore, Maryland, the same renowned institution where he would later make his mark in the field of cancer genetics. As a young teen, he was an enthusiast and independent consumer of books, one of which helped shape...
Eliezer Robinson, MD, Traveled a Long, Hard Road and Became an International Leader in Oncology
Eliezer Robinson, MD, was born in Vienna, Austria, on June 17, 1931. At that time, Vienna, a bustling and prosperous city, was an important center of Jewish culture and education. Jews made up a large portion of the city’s professional class of doctors, lawyers, bankers, and artists. Dr. Robinson...
Narratives in Oncology
Keith Witmer received his Bachelor’s degree in Fine Arts from Otis/Parsons School of Design. He subsequently launched his career in advertising and publication with a commanding presence, initially using pen and ink and scratchboard mediums. Working with clients such as FedEx, pple Computer,...
Scott Gottlieb, MD, Receives Confirmation as FDA Commissioner
Statement by 2016–2017 ASCO President Daniel F. Hayes, MD, FACP, FASCO: “The American Society of Clinical Oncology (ASCO) congratulates Scott Gottlieb, MD, on his confirmation as Commissioner of the U.S. Food and Drug Administration (FDA). With more than 1.7 million new cancer diagnoses made in...
Susan G. Komen Names Eight Advisors to Guide Breast Cancer Research Program
Susan G. Komen announced new advisory roles for eight leaders in breast cancer who will guide the organization’s education and advocacy work, public health efforts, and help direct Komen’s $920 million research program. On April 1, Jennifer A. Pietenpol, PhD, of Vanderbilt-Ingram Cancer Center,...
Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles
Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...
Special Awards and Lectures Presented During 2017 ASCO Annual Meeting
Recipients of ASCO’s Notable Awards and Lectures are individuals who have made extraordinary contributions to the research and treatment of patients with cancer. These individuals were honored during several special sessions held during ASCO’s 53rd Annual Meeting, where more than 30,000 physicians, ...
Robert Vonderheide, MD, DPhil, Named Director of Abramson Cancer Center
Robert Vonderheide, MD, DPhil, has been named the new Director of the Abramson Cancer Center (ACC) of the University of Pennsylvania. He is the Hanna Wise Professor in Cancer Research at the Perelman School of Medicine and currently serves as the ACC’s Associate Director for Translational Research ...
Pioneer in Geriatric Oncology, Hyman Muss, MD, Continues to Improve Care for Older Patients
Hyman Muss, MD, a pioneer in geriatric oncology, considers himself “a real Brooklyn boy.” His father was a dentist, and his uncle was a general practitioner. “They both practiced out of a small brownstone house in Brownsville-Crown Heights. It was sort of reminiscent of the famous movie The Last...
ASCO 2017 Presents Women Who Conquer Cancer Mentorship Award
First presented in 2016 by the Conquer Cancer Foundation, the Women Who Conquer Cancer Mentorship Award honors extraordinary female leaders in oncology who have both excelled as mentors and demonstrated outstanding commitment to the professional development of women colleagues as clinicians,...
Distinguished Pediatric Oncologist Anna T. Meadows, MD, Led the Way for Studies in Childhood Cancer Survivors
Anna T. Meadows, MD, an internationally distinguished pediatric oncologist who led paradigm-changing survivorship research and clinical care of children with cancer, had an unusual introduction to the United States. “My mother was traveling abroad on vacation and got married in Poland. Although...
FDA Oncology Drug Approvals Granted Between August 2016 and May 18, 2017
Pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, received regular approval from the U.S. Food and Drug Administration (FDA) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing...
Waun Ki Hong, MD, FACP, Helped Change the Standard of Care in Laryngeal Cancer, Now Focuses on Chemoprevention and Precision Medicine
Waun Ki Hong, MD, FACP, one of the nation’s leading experts in head and neck and lung cancers, was born in South Korea and grew up in a tiny village outside the nation’s capital of Seoul. Number six of seven siblings, Dr. Hong described his early life in the cozy village as blissful, until the...
Final Overall Survival Results of TH3RESA Trial in Breast Cancer
The final overall survival results of the phase III TH3RESA trial indicate a 32% reduction in risk of death with ado-trastuzumab emtansine (Kadcyla) vs treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer. The findings were reported in The ...
Clinical Researcher George P. Canellos, MD, Closely Involved With Two of the Most Influential Treatments in Cancer Care
George P. Canellos, MD, President of ASCO from 1993 to 1994, was born in Boston on November 1, 1934. “I came from a business family and never wanted to do business at all. As long back as I can remember, I always found medicine attractive—not only because you could help people, but you could also...
Daniel Von Hoff, MD, FACP, Receives Gold Medal From Columbia University
Daniel Von Hoff, MD, FACP—Distinguished Professor, Physician-in-Chief, and Director of Molecular Medicine at the Translational Genomics Research Institute—received a gold medal for excellence in clinical medicine from his alma mater, Columbia University. Columbia University College of Physicians...
Nobel Prize in Physiology or Medicine: Laureates in Oncology
The Nobel Prize in Physiology or Medicine has been awarded to many individuals whose research directly impacted the understanding of cancer: In 2008 to Harald zur Hausen, for his discovery of human papillomavirus causing cervical cancer In 2005 to J. Robin Warren and Barry J. Marshall, for their...
Nobel Laureate David Baltimore, PhD, Plays Integral Role in Linking Cell Biology and Cancer Genetics
David Baltimore, PhD, whose work profoundly influenced international science, was born on March 7, 1938, in Queens, New York, to Gertrude and Richard Baltimore. While he was in second grade, the family moved to Great Neck, New York, a middle-class suburb with top-notch public schools. “My father...
Renowned Hematologist Mojtaba Akhtari, MD, Reflects on a New Era in Treating Blood Cancers
The nationally recognized hematologist-oncologist Mojtaba Akhtari, MD, was born and reared in Tehran, Iran. “In my early years, I had a couple of cousins who were medical students. When I visited them in their homes, I was fascinated with the images in their medical text books. I would flip the...
Lack of Access to Transfusions Limits Hospice Use by Patients With Blood Cancer
A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies. The findings, published by Odejide et al in Cancer, help explain...
Tai Chi Chih vs Cognitive Behavioral Therapy for Insomnia in Breast Cancer Survivors
In a study reported in the Journal of Clinical Oncology by Irwin et al, Tai Chi Chih, a form of movement meditation, was noninferior to insomnia-specific cognitive behavioral therapy in improving insomnia in breast cancer survivors. Study Details In the study, 90 patients with insomnia from the...
ASCO Presidents Through the Years
2016–2017 Daniel Hayes, MD 2015–2016 Julie Vose, MD, MBA 2014–2015 Peter Paul Yu, MD, FACP 2013–2014 Clifford A. Hudis, MD, FACP 2012–2013 Sandra M. Swain, MD 2011–2012 Michael P. Link, MD 2010–2011 George W. Sledge, Jr, MD 2009–2010 Douglas W. Blayney, MD 2008–2009 Richard...
ASCO President, Bruce E. Johnson, MD, FASCO, Participates in Key Research With EGFR Mutation in Lung Cancer
Bruce E. Johnson, MD, FASCO, 2017–2018 ASCO President, was born in St. Peter, Minnesota, and grew up on a rural dairy farm. “Neither of my parents had college degrees, but working on a dairy farm with them gave me a solid work ethic. I was working outside on the farm before I was 10 years old. In...
